Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006)
Erica de Camargo Ferreira E Vasconcellos, Maria Inês Fernandes Pimentel, Armando de Oliveira Schubach, Raquel de Vasconcellos Carvalhaes de Oliveira, Rilza Beatriz Azeredo-Coutinho, Fátima da Conceição Silva, Mariza de Matos Salgueiro, João Soares Moreira, Maria de Fátima Madeira, Cibele Baptista, Cláudia Maria Valete-Rosalino, Erica de Camargo Ferreira E Vasconcellos, Maria Inês Fernandes Pimentel, Armando de Oliveira Schubach, Raquel de Vasconcellos Carvalhaes de Oliveira, Rilza Beatriz Azeredo-Coutinho, Fátima da Conceição Silva, Mariza de Matos Salgueiro, João Soares Moreira, Maria de Fátima Madeira, Cibele Baptista, Cláudia Maria Valete-Rosalino
Abstract
We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy. Each treatment consisted of one to four intralesional applications of MA at 15-day intervals. Patients' age ranged from 3 to 90 years; fourteen were females. Intralesional treatment in the absence of any relevant toxicity was successful in 20 (83.3%) patients. Three patients required additional treatment with amphotericin B and one required systemic MA. None of the patients developed mucosal lesions when followed up to 60 months. Intralesional MA is an effective and less toxic alternative treatment of patients with CL and contraindication to systemic therapy.
Figures
Source: PubMed